Organogenesis Holdings Inc. Class A Common Stock
ORGOUnited States
5 filed reports · 290 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 844 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 835 | Dec 2025 |
Financial data
290 concepts · 1,679 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial287 concepts · 1,649 facts · Dec 2023 to Jun 2026
- Allowance for doubtful accounts receivable14 · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Profit loss13 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Goodwill impairment loss12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Net income loss available to common stockholders basic12 · Dec 2023 to Jun 2026
- Net income loss available to common stockholders diluted12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating costs and expenses12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- Accrued expenses and other current liabilities11 · Dec 2023 to Jun 2026
- Adjustment for excess and obsolete inventories11 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect11 · Dec 2023 to Jun 2026
- Deferred income tax expense benefit11 · Dec 2023 to Jun 2026
Product2 concepts · 28 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
- us-gaap:OtherIncome4 · Jun 2025 to Dec 2025
Geography1 concepts · 2 facts · Mar 2026 to Jun 2026
- Restructuring charges2 · Mar 2026 to Jun 2026
Segments
30 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service2 members · 28 facts
- Grant16 · Dec 2023 to Jun 2026
- Product12 · Dec 2023 to Jun 2026
Statement geographical1 member · 2 facts
- FL2 · Mar 2026 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
- FY2026 Q1May 8, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 7, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.